As part of our standard formulary management process of implementing formulary updates twice per year, the next scheduled update will be for 1 de octubre de 2019 for our commercial benefit programs. These updates do not include BlueCHiP for Medicare. All members impacted by the changes received individual notifications by 1 de septiembre de 2019.

The most significant change in coverage involves a transition of select products, including all forms of Infliximab, Entyvio, and Immune Globulin, from pharmacy coverage to medical coverage. These products will no longer require distribution through the BCBSRI specialty pharmacy network. Access through the specialty pharmacy network will remain supported, but not required.

You can view the summary that provides details on the changes scheduled by clicking here.